Definium Therapeutics reports positive Phase 3 topline for DT120 ODT
Definium Therapeutics announced positive topline results from its Phase 3 Panorama study of DT120 ODT for generalized anxiety disorder.
Story updates
11:22:34 AM UTC
SquawkNews
Definium Therapeutics, Inc. (NASDAQ:DFTX) reported Phase 3 Panorama success as DT120 ODT 100µg cut HAM—A by 5.1 points vs placebo with rapid Day 2 responses, high adherence and mild transient AEs, while the company granted 56,650 inducement options to three non—executive hires vesting over four yea…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.